4.1 Article

Age and Sex Differences in Reward Behavior in Adolescent and Adult Rats

期刊

DEVELOPMENTAL PSYCHOBIOLOGY
卷 56, 期 4, 页码 611-621

出版社

WILEY
DOI: 10.1002/dev.21127

关键词

adolescent; sex; learning; extinction; reward devaluation; rat; Pavlovian approach; reacquisition; reward processing

资金

  1. National Institute on Drug Abuse [R01 DA029815]

向作者/读者索取更多资源

Compared to adults, adolescents are at heightened risk for drug abuse and dependence. One of the factors contributing to this vulnerability may be age-dependent differences in reward processing, with adolescents approaching reward through stimulus-directed, rather than goal-directed, processes. However, the empirical evidence for this in rodent models of adolescence, particularly those that investigate both sexes, is limited. To address this, male and female rats that were adolescents (P30) or adults (P98) at the start of the experiment were trained in a Pavlovian approach (PA) task and were subsequently tested for the effects of reward devaluation, extinction, and re-acquisition. We found significant interactions between age and sex: females had enhanced acquisition of PA and poorer extinction, relative to males, while adolescents and females were less sensitive to reward devaluation than male adults. These results suggest that females and adolescents exhibit reward behavior that is more stimulus-directed, rather than goal-directed. (c) 2013 Wiley Periodicals, Inc. Dev Psychobiol 56: 611-621, 2014.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Meeting Abstract Oncology

Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance.

J. Kellogg Parsons, Peter A. Pinto, Howard L. Parnes, Christian P. Pavlovich, Edward M. Uchio, Mike Minh Nguyen, Hyung Lae Kim, James L. Gulley, Houssein Abdul Sater, Christina Jamieson, Chiu-Hsieh Hsu, Malgorzata E. Wojtowicz, Jeffrey Schlom, Renee Nicole Donahue, Sara Centuori, Shania Bailey, Julie E. Bauman, H. H. Chow

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).

Emerson A. Lim, Michael Thomas Schweizer, Kim N. Chi, Rahul Raj Aggarwal, Neeraj Agarwal, James L. Gulley, Edward F. Attiyeh, James Greger, Shujian Wu, Pharavee Jaiprasart, John Loffredo, Nibedita Bandyopadhyay, Hong Xie, Aaron Richard Hansen

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Medicine, Research & Experimental

Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity

Youji Hong, Yvette Robbins, Xinping Yang, Wojciech K. Mydlarz, Anastasia Sowers, James B. Mitchell, James L. Gulley, Jeffrey Schlom, Sofia R. Gameiro, Cem Sievers, Clint T. Allen

Summary: This study demonstrates that local administration of a tumor-targeted IL-12 antibody fusion protein can achieve potent immune control of established tumors with low doses to avoid systemic toxicity. The treatment leads to reinvigoration and proliferation of exhausted T lymphocytes, induction of Th1 immunity, and a decrease in regulatory T cells and suppressive myeloid cells. Single-cell analysis also reveals similar IL-12 receptor expression patterns in human head and neck carcinomas.

JCI INSIGHT (2022)

Article Immunology

Characteristics of patients admitted to the ICU with Kaposi sarcoma herpesvirus-associated diseases

Megan E. Hansen, Ralph Mangusan, Kathryn Lurain, Thomas Odeny, Jomy George, Crystal Lu, Maura Manion, Anaida Widell, Irene Ekwede, Denise Whitby, James L. Gulley, Sameer S. Kadri, Jason M. Elinoff, Amisha Barochia, Parizad Torabi-Parizi, Thomas S. Uldrick, Robert Yarchoan, Ramya Ramaswami

Summary: This retrospective study examined the clinical data of HIV and KAD patients admitted to the ICU. The results showed that the majority of patients had well controlled HIV, and a proportion of patients were diagnosed with additional KADs upon admission. Critical illness did not prevent some patients from receiving KAD-directed therapy in the ICU.
Article Oncology

Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer

Arun Rajan, Jhanelle E. Gray, Siddhartha Devarakonda, Ruemu Birhiray, Borys Korchin, Erika Menius, Renee N. Donahue, Jeffrey Schlom, James L. Gulley

Summary: CV301 in combination with PD-1 inhibitors is safe and clinically active in advanced NSCLC patients, without an increased frequency or severity of immune-related adverse events.

INTERNATIONAL JOURNAL OF CANCER (2023)

Review Oncology

Molecular Pathways and Mechanisms of TGFb in Cancer Therapy

Mary Helen Barcellos-Hoff, James L. Gulley

Summary: Despite the increasing number of TGFI3 inhibitors tested in cancer patients, there has been no clinical benefit achieved yet. The main obstacle to effective TGFI3 inhibition is the diverse mechanisms by which TGFI3 promotes tumor growth. TGFI3 is involved in regulating DNA repair and immune suppression, which can be used to synergize genotoxic therapy and immunotherapy for the benefit of cancer patients.

CLINICAL CANCER RESEARCH (2023)

Article Pharmacology & Pharmacy

In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation

Cody J. Peer, Keith T. Schmidt, Oluwatobi Arisa, William J. Richardson, Koosha Paydary, Daniel A. Goldstein, James L. Gulley, William D. Figg, Mark J. Ratain

Summary: Atezolizumab, a humanized monoclonal antibody against PD-L1, was approved in 2016. Standard dose regimens result in high plasma concentrations, indicating the need for alternative dosing strategies to reduce exposure burden.

JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Oncology

Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial

Alexander Spira, Michael S. Wertheim, Edward J. Kim, Benjamin Tan, Heinz-Josef Lenz, Petros Nikolinakos, Patricia L. Rich, Genevieve Jehl, Andreas Machl, Rena Ito, James L. Gulley, Scott Kopetz

Summary: A phase I study on bintrafusp alfa in heavily pretreated patients with colorectal cancer showed promising early signs of clinical efficacy and manageable safety profile.

ONCOLOGIST (2023)

Article Oncology

A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors

Margaret E. Gatti-Mays, Nicholas P. Tschernia, Julius Strauss, Ravi A. Madan, Fatima H. Karzai, Marijo Bilusic, Jason Redman, Houssein Abdul Sater, Charalampos S. Floudas, Nicole J. Toney, Renee N. Donahue, Caroline Jochems, Jennifer L. Marte, Deneise Francis, Sheri McMahon, Elizabeth Lamping, Lisa Cordes, Jeffrey Schlom, James L. Gulley

Summary: The results of this study showed that biweekly NHS-IL12 treatment was safe for patients with advanced cancers. NHS-IL12 is a first-in-class fusion protein used in this trial. Patients received NHS-IL12 every two weeks, and the results demonstrated stable disease status for the patients.

ONCOLOGIST (2023)

Article Oncology

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

Emerson A. Lim, Michael T. Schweizer, Kim N. Chi, Rahul Aggarwal, Neeraj Agarwal, James Gulley, Edward Attiyeh, James Greger, Shujian Wu, Pharavee Jaiprasart, John Loffredo, Nibedita Bandyopadhyay, Hong Xie, Aaron R. Hansen

Summary: PSMA expression is maintained in all stages of prostate cancer. In a phase 1 study, a bispecific antibody targeting PSMA-expressing tumor cells and CD3-expressing T cells showed manageable cytokine release syndrome and temporary decline in PSA in patients with metastatic castration-resistant prostate cancer. Treatment-related deaths and radiographic responses were not observed. PSMA is a potential therapeutic target for T-cell redirection in prostate cancer.

CLINICAL GENITOURINARY CANCER (2023)

Article Oncology

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies

Michael B. Atkins, Paolo A. Ascierto, David Feltquate, James L. Gulley, Douglas B. Johnson, Nikhil Khushalani, Jeffrey Sosman, Timonthy A. Yap, Harriet Kluger, Ryan J. Sullivan, Hussein Tawbi

Summary: Immunotherapy alone does not work for all tumors, so combining it with signal transduction inhibitors, such as antiangiogenic therapies, can enhance its effectiveness. Combination therapies with immunotherapy have shown improved antitumor activity in various solid tumor settings and have received regulatory approval for the treatment of several types of cancer. However, many patients still experience progression after combination treatment, highlighting the need for new strategies to address resistance to immunotherapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Review Oncology

Vaccinating against cancer: getting to prime time

Ryan Chang, James L. Gulley, Lawrence Fong

Summary: Immunotherapies, such as immune checkpoint inhibitors and cellular therapies, have revolutionized cancer treatment, but the development of successful cancer vaccines remains challenging. Only two vaccines have shown improved survival in advanced disease: sipuleucel-T and talimogene laherparepvec, which target specific antigens and utilize tumors in situ to prime responses. In this review, we examine the challenges and opportunities in developing therapeutic cancer vaccines.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Obstetrics & Gynecology

Prenatal syphilis screening among pregnant Medicaid enrollees by sexually transmitted infection history as well as race and ethnicity

Lindsey R. Hammerslag, Rachel E. Campbell-Baier, Caitlin A. Otter, Ana Lopez-De Fede, Jheramy P. Smith, L. Angel Whittington, Larry J. Humble, Eddy R. Myers, Susan R. Kennedy, Jeffery C. Talbert, William S. Pearson

Summary: This study examines the association between prenatal syphilis screening rates and sexually transmitted infection history or patient characteristics in three states with high rates of congenital syphilis. The results show that previous sexually transmitted infections and continuous Medicaid enrollment before pregnancy are associated with higher rates of syphilis screening. However, Medicaid claims alone do not fully capture the patients' sexually transmitted infection history. The overall screening rates are lower than expected, especially in the third trimester, and there are disparities in early screening for non-Hispanic Black women compared to non-Hispanic White women.

AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY MFM (2023)

Article Medicine, Research & Experimental

Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer

Jason M. Redman, Jay Friedman, Yvette Robbins, Cem Sievers, Xinping Yang, Wiem Lassoued, Andrew Sinkoe, Antonios Papanicolau-Sengos, Chyi-Chia Lee, Jennifer L. Marte, Evrim Turkbey, Wojtek Mydlarz, Arjun Joshi, Nyall R. London, Matthew Pierce, Rodney Taylor, Steven Hong, Andy Nguyen, Patrick Soon-Shiong, Jeffrey Schlom, James L. Gulley, Clint T. Allen

Summary: Neoadjuvant immunotherapy with dual PD-L1 and TGF-beta blockade can safely enhance tumor antigen-specific immunity and improve survival rate in patients with HPV-unrelated HNSCC. Myeloid cell infiltration in the tumor microenvironment may play a crucial role in enhancing antitumor immune response.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Meeting Abstract Oncology

STAR0602, a novel TCR agonist antibody, demonstrates potent antitumor activity in refractory solid tumor models through the expansion of a novel, polyclonal effector memory T cell subset

J. L. Gulley, A. Bayliffe, R. Donahue, Y. T. Tsai, K. Liu, M. Katraggada, J. Hsu, L. L. Siu, E. J. Wherry, R. Chopra, J. Schlom, Z. Su

EUROPEAN JOURNAL OF CANCER (2022)

暂无数据